Nature Communications (Mar 2017)

PABPN1 gene therapy for oculopharyngeal muscular dystrophy

  • A. Malerba,
  • P. Klein,
  • H. Bachtarzi,
  • S. A. Jarmin,
  • G. Cordova,
  • A. Ferry,
  • V. Strings,
  • M. Polay Espinoza,
  • K. Mamchaoui,
  • S. C. Blumen,
  • J. Lacau St Guily,
  • V. Mouly,
  • M. Graham,
  • G. Butler-Browne,
  • D. A. Suhy,
  • C. Trollet,
  • G. Dickson

DOI
https://doi.org/10.1038/ncomms14848
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 14

Abstract

Read online

Oculopharyngeal muscular dystrophy is caused by trinucleotide repeat expansions in thePABPN1gene. Here the authors use AAV-based gene therapy to knockdown the mutant gene and replace it with a wild-type allele, and show effectiveness in mice and in patient cells.